» Articles » PMID: 11675329

Purification and Ex Vivo Expansion of Postnatal Human Marrow Mesodermal Progenitor Cells

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2001 Oct 25
PMID 11675329
Citations 218
Authors
Affiliations
Soon will be listed here.
Abstract

It is here reported that mesenchymal stem cells known to give rise to limb-bud mesoderm can, at the single-cell level, also differentiate into cells of visceral mesoderm and can be expanded extensively by means of clinically applicable methods. These cells were named mesodermal progenitor cells (MPCs). MPCs were selected by depleting bone marrow mononuclear cells from more than 30 healthy human donors of CD45(+)/glycophorin-A (GlyA)(+) cells. Cells were cultured on fibronectin with epidermal growth factor and platelet-derived growth factor BB and 2% or less fetal calf serum. It was found that 1/5 x 10(3) CD45(-)GlyA(-) cells, or 1/10(6) bone marrow mononuclear cells, gave rise to clusters of small adherent cells. Cell-doubling time was 48 to 72 hours, and cells have been expanded in culture for more than 60 cell doublings. MPCs are CD34(-), CD44(low), CD45(-), CD117 (cKit)(-), class I-HLA(-), and HLA-DR(-). MPCs differentiated into cells of limb-bud mesoderm (osteoblasts, chondrocytes, adipocytes, stroma cells, and skeletal myoblasts) as well as visceral mesoderm (endothelial cells). Retroviral marking was used to definitively prove that single MPCs can differentiate into cells of limb bud and visceral mesoderm. Thus, MPCs that proliferate without obvious senescence under clinically applicable conditions and differentiate at the single-cell level not only into mesenchymal cells but also cells of visceral mesoderm may be an ideal source of stem cells for treatment of genetic or degenerative disorders affecting cells of mesodermal origin.

Citing Articles

models of leukemia development: the role of very small leukemic stem-like cells in the cellular transformation cascade.

Lica J, Jakobkiewicz-Banecka J, Hellmann A Front Cell Dev Biol. 2025; 12():1463807.

PMID: 39830209 PMC: 11740207. DOI: 10.3389/fcell.2024.1463807.


Impact of Environmental and Epigenetic Changes on Mesenchymal Stem Cells during Aging.

Smith N, Shirazi S, Cakouros D, Gronthos S Int J Mol Sci. 2023; 24(7).

PMID: 37047469 PMC: 10095074. DOI: 10.3390/ijms24076499.


The Use of Mesenchymal Stem Cells in the Complex Treatment of Kidney Tuberculosis (Experimental Study).

Muraviov A, Vinogradova T, Remezova A, Ariel B, Gorelova A, Orlova N Biomedicines. 2022; 10(12).

PMID: 36551818 PMC: 9775022. DOI: 10.3390/biomedicines10123062.


Allogeneic Bone Impregnated with Biodegradable Depot Delivery Systems for the Local Treatment of Joint Replacement Infections: An In Vitro Study.

Prokes L, Snejdrova E, Soukup T, Malakova J, Frolov V, Loskot J Molecules. 2022; 27(19).

PMID: 36235024 PMC: 9571001. DOI: 10.3390/molecules27196487.


Understanding the Molecular Basis of iPSC Reprogrammed Cells to Fulfil Their Expectations in Future Clinical Applications.

Gonzalez-Fernandez V, Sevilla A Cells. 2022; 11(17).

PMID: 36078122 PMC: 9454435. DOI: 10.3390/cells11172714.